Lupin Limited has entered into partnerships with Unitaid, the Clinton Health Access Initiative (CHAI), The Aurum Institute, and other global procurement agencies for supporting tuberculosis (TB) prevention treatment.

According to the Indian pharma company, the TB prevention treatment will be launched in 138 countries, including several low-and middle-income countries that are faced with a large burden of TB.

Through the agreement with the procurement agencies, Lupin will roll out a couple of new formulations, which include a fixed-dose combination of Rifapentine and Isoniazid and Rifapentine 300 mg standalone tablets.

Nilesh Gupta — Lupin Managing Director said: “We are committed to enhancing the global access to affordable and high-quality drugs and APIs for the treatment of tuberculosis.

“We are glad to partner on these important products as this closely aligns with our mission of building better health, globally. Through this, we will further reinforce our long legacy to provide shorter, more patient-friendly treatment options to prevent TB.”

Last year, Lupin secured a non-exclusive license from non-profit drug developer TB Alliance for manufacturing the anti-TB drug pretomanid.

  Clinton Health Access Initiative, India, Isoniazid, Lupin, Nilesh Gupta, Rifapentine, The Aurum Institute, tuberculosis, Unitaid